Peijia Medical's TaurusTrio valve system NMPA registration accepted
Peijia Medical Limited (HKEX:9996) announced that the NMPA has accepted its registration application for the TaurusTrio™ Transcatheter Aortic Valve (TAV) System. The TaurusTrio™ system, developed and manufactured under an exclusive license from JenaValve Technology, Inc., targets patients with severe aortic regurgitation via transfemoral access. The system received priority status under the Special Review and Approval Procedure for Innovative Medical Devices in June 2023, which should accelerate its appraisal and approval process. While the company acknowledges that ultimate market success is not guaranteed, this marks a significant step in expanding Peijia Medical's product portfolio and addressing a critical medical need in China.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Peijia Medical publishes news
Free account required • Unsubscribe anytime